RHEACELL GmbH & Co. KG
PrivateLast Round
Corporate Funding
Jul 30, 2020
Total Funding Raised
$70.71M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
RHEACELL GmbH & Co. KG is a biopharmaceutical company that develops innovative stem cell-based therapies for severe immune and inflammation-driven diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RHEACELL GmbH & Co. KG Comparables
Compare RHEACELL GmbH & Co. KG with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Castle Creek Biosciences | 74% | |
| Abeona Therapeutics Inc. | 74% | |
| Longeveron | 74% | |
RHEACELL GmbH & Co. KG Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Jul 30, 2020 |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 23, 2026
Grew 21% QoQ, from 67 to 81 employees.
- May 12, 2026
Monthly visitors grew 49% MoM, reaching 2.3K.
RHEACELL GmbH & Co. KG Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about RHEACELL GmbH & Co. KG's valuation, stock price, and market status.